The Indian Pharmaceutical Market (IPM) has registered a growth of 47.8 per cent for the month of May 2021, as against a growth of 51.5 per cent for the month of April 2021.
According to AIOCD AWACS report, the IPM has recorded a strong growth of 10.8 % value growth for moving annual total (MAT) basis during May 2021.
The top areas like anti-infectives, cardiac, gastro and nutritionals show a strong integer growth for moving annual total May 2021 period also .
“As the country recovers another time from the impact of Covid wave, pharmaceutical industry has been showing strong signals of recovery within the previous couple of months,” the report said.
“While we’ve been successful to an excellent extent in managing the pandemic, the treatment protocol itself has let to several more unwanted effects like increased blood glucose levels, opportunity infections like black/white/yellow fungus, etc. This, successively has led to extend in consumption of medicine needed to manage these effects,” the AIOCD AWACS report said.
Companies operating in Covid treatment therapy segments have gained substantially through bumper sales and substantial changes in brand and company ranking seen for April 2021, the report further said.
While India Ratings and Research stated that the expansion in India’s pharmaceutical market (IPM) during May 2021 was led by a coffee base effect, as IPM declined by 8.5% year on year in May 2020 thanks to the lockdown. IPM growth would are stronger on an adjusted basis.
The agency also estimates the pharmaceutical market to grow of 8%-10% year on year in size during FY 2022.
The rating agency said that acute therapies like anti-infectives, analgesic and vitamins witnessed sales growth of 141.9% year on year, 50.3% year on year and 59.8% year on year respectively, while gastro grew 47.7% year on year during May 2021.